Journal of the American College of Surgeons
Volume 208, Issue 2 , Pages 202-209 , February 2009

Impact of Patient Age and Comorbidity on Surgeon Versus Oncologist Preferences for Adjuvant Chemotherapy for Stage III Colon Cancer

Abstract presented at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.

  • Monika K. Krzyzanowska, MD, MPH

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    • Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorrespondence address: Monika K Krzyzanowska, MD, MPH, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Ste 5-206, Toronto, Ontario M5G 2M9, Canada
    • ,
  • Meredith M. Regan, ScD

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Mark Powell, MA, MEd

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
    • ,
  • Craig C. Earle, MD, MS

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA
    • ,
  • Jane C. Weeks, MD, MSc

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
    • Department of Medicine, Harvard Medical School, Boston, MA

Received 5 June 2008 ,Revised 6 October 2008 ,Accepted 6 October 2008.

References 

  1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973−1999, featuring implications of age and aging on US cancer burden. Cancer. 2002;94:2766–2792
  2. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–1450
  3. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358
  4. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321–326
  5. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997;15:246–250
  6. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850–857
  7. Mahoney T, Kuo YH, Topilow A, Davis JM. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000;135:182–185
  8. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001;7:213–218
  9. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192–1202
  10. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005;294:2703–2711
  11. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–1097
  12. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol. 2002;20:3992–3998
  13. Sundararajan V, Mitra N, Jacobson JS, et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002;136:349–357
  14. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity (Analysis of a large scale phase III trial). Cancer. 1995;75:11–17
  15. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number (Tomudex International Study Group). Eur J Cancer. 1998;34:1871–1875
  16. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol. 1998;16:3537–3541
  17. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671–8678
  18. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–1338
  19. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580–1584
  20. Liang W, Burnett CB, Rowland JH, et al. Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol. 2002;20:1008–1016
  21. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med. 1996;124:414–421
  22. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumorregistry database. Med Care. 1993;31:732–748
  23. In:  Rossi PH,  Nock SL editor. Measuring social judgements: the factorial survey approach. Beverly Hills, CA: Sage Publications; 1982;
  24. Kellerman SE, Herold J. Physician response to surveys (A review of the literature). Am J Prev Med. 2001;20:61–67
  25. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst. 2001;93:501–515
  26. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–1300
  27. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?. J Clin Oncol. 2008;26:2532–2537
  28. Gross CP, McAvay GJ, Krumholz HM, et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med. 2006;145:646–653
  29. Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109:2410–2419
  30. Luo R, Giordano SH, Zhang DD, et al. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer. 2007;109:975–982
  31. Mandelblatt JS, Berg CD, Meropol NJ, et al. Measuring and predicting surgeons' practice styles for breast cancer treatment in older women. Med Care. 2001;39:228–242

 Disclosure Information: Nothing to disclose.

 Supported by an American Society of Clinical Oncology Young Investigator Award and a Fellowship Award from the National Cancer Institute of Canada. Neither sponsor had a role in the design or interpretation of this study.

PII: S1072-7515(08)01530-5

doi: 10.1016/j.jamcollsurg.2008.10.016

Journal of the American College of Surgeons
Volume 208, Issue 2 , Pages 202-209 , February 2009

Article Tools

* Image Usage & Resolution